108. Vibe Bio launches to transform drug development, Alok Tayi Ph.D. and Susanna Harris Ph.D.

108. Vibe Bio launches to transform drug development, Alok Tayi Ph.D. and Susanna Harris Ph.D.

Our guest this week is one of our hosts, Alok Tayi, and he has some exciting news. The official launch of his new company, Vibe Biotechnology, building a global community of patients, scientists, and partners around a shared mission to cure rare diseases. Vibe Bio's novel approach seeks to scale the development of treatments sustainably and provides patient communities unprecedented ownership over the results. Alok is a scientist by trade, with over 15 years under his belt including a PhD at Northwestern - and time spent at Harvard under a successful biotech founder. He then went on to start multiple biotech software companies - securing over $100M in total venture funding along the way. Through his own personal and professional experience, Alok has realized that the families of patients with rare diseases have plenty of hope - but what they need is help. Not necessarily finding the right potential therapeutic option - but actually funding it. That’s where the Vibe community steps in - vetting out which drug development programs have the highest potential and financing the process via crypto token sales. Tapping into the crypto market opens up a wealth of new opportunities when it comes to tackling some of these major rare diseases. Vibe’s aim is to give families not only the community of support - but the genuine power to pursue a cure for any rare disease at scale - an issue that impacts 1 in 10 Americans. Sit back, relax, and we hope you enjoy this enlightening conversation between Alok and our wonderful guest host Susanna Harris, PhD.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Juni 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Maj 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mars 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mars 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
medicinvetarna
svd-nyhetsartiklar
bildningspodden
rss-spraket
rss-vetenskapsradion
det-morka-psyket
sexet
rss-kriminologerna
dumforklarat
rss-ufobortom-rimligt-tvivel
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli
rss-vetenskapsradion-2
rss-arkeologi-historia-podden-som-graver-i-vart-kulturlandskap
halsorevolutionen
rss-lara-fran-larda-en-fackbok-och-en-forfattare
parkinsonpodden